CJC-1295 + Ipamorelin

Overview

This research blend pairs Ipamorelin (5mg), a selective growth hormone secretagogue acting on GHSR-1a, with CJC-1295 (5mg), a stabilized analog of growth hormone-releasing hormone. The combination is one of the most-referenced peptide pairings in research on the somatotropic axis.

Research Background

Ipamorelin and CJC-1295 act on parallel pathways of GH release: Ipamorelin via the ghrelin receptor and CJC-1295 via the GHRH receptor. Combined preparations allow investigators to study their additive and synergistic effects on pituitary GH secretion.

Storage & Handling

Store lyophilized peptide at -20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within recommended timeframes. Handle under sterile laboratory conditions and avoid repeated freeze-thaw cycles.

Disclaimer:
This product is for laboratory research use only. It is not intended for human or animal consumption or for use in any diagnostic, therapeutic, or clinical applications.

Ipamorelin selectively activates GHSR-1a (the ghrelin receptor), triggering Gq/PLC/Ca²⁺ signaling on pituitary somatotrophs. CJC-1295 binds the GHRH receptor, engaging Gs/cAMP signaling. The two pathways converge on enhanced pulsatile growth hormone release, with the combination producing larger and more sustained GH responses than either peptide alone in published research models.

The combination is studied in research on pituitary GH secretion patterns, body composition, sleep biology, and metabolic regulation. It is one of the most widely referenced peptide pairings in growth hormone axis research.